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Context: Angiopoietin-like 3 (ANGPTL3) deficiency in plasma due to loss-of-function gene mutations
results in familial combined hypobetalipoproteinemia type 2 (FHBL2) in homozygotes. However, the
lipid phenotype in heterozygotes is much milder and does not appear to relate directly to ANGPTL3
levels. Furthermore, the low-density lipoprotein (LDL) phenotype in carriers of ANGPTL3 mutations is
unexplained.
Objective: To determine whether reduction below a critical threshold in plasma ANGPTL3 levels is a
determinant of lipoproteinmetabolism in FHBL2, and to determine whether proprotein convertase
subtilisin kexin type 9 (PCSK9) is involved in determining low LDL levels in this condition.
Design: We studied subjects from 19 families with ANGPTL3 mutations and subjects with familial
combined hypobetalipoproteinemia type 1 (FHBL1) due to truncated apolipoprotein B (apoB) species.
Results: First, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and HDL
and LDL particle concentration correlated with plasma ANGPTL3 levels but only when the latter
was ,25% of normal (,60 ng/dL). Second, the very low-density lipoprotein particle concentration
correlated strongly with plasma ANGPTL3 when the latter was,58% of normal. Third, both FHBL1
and FHBL2 subjects showed low levels ofmature and LDL-bound PCSK9 and higher levels of its furin-
cleaved form. Finally, LDL-bound PCSK9 is protected from cleavage by furin and binds to the LDL
receptor more strongly than apoB-free PCSK9.
Conclusions: Our results suggest that the hypolipidemic effects of ANGPTL3 mutations in FHBL2 are
dependent on a threshold of plasma ANGPTL3 levels, with differential effects on various lipoprotein
particles. The increased inactivationofPCSK9by furin in FHBL1andFHBL2 is likely to cause increasedLDL
clearanceandsuggestsnovel therapeuticavenues. (JClinEndocrinolMetab102:3340–3348,2017)
F amilial combined hypobetalipoproteinemia type 2(FHBL2) is characterized by a unique lipid profile,
which includes low levels of triglycerides (TGs), low-density
lipoprotein (LDL) cholesterol (LDL-c), and high-density
lipoprotein (HDL) cholesterol (HDL-c) but unaffected li-
poprotein(a) levels (1, 2). However, the concentration and
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size of each lipoprotein particle in FHBL2 is not well
characterized. The full phenotype of FHBL2 is caused
by homozygous mutations in angiopoietin-like protein 3
(ANGPTL3), a secreted 460-amino acid protein produced
mainly by the liver (3, 4), leading to reduced plasma levels.
FHBL2 subjects are healthy, do not have fatty liver disease,
and have an apparent lower risk of developing diabetes
mellitus (5). It was recently shown that ANGPTL3 de-
ficiency is also associated with protection from coronary
artery disease (6). No clear gene–dosage effect of ANGPTL3
mutations on all lipoprotein levels has been found, because
heterozygotes show only a mild hypolipidemic phenotype,
with LDL mostly in the low-normal range (7). Most of the
mutations inANGPTL3 influence its plasma levels; however,
the effect of these changes on plasma lipids and lipoproteins
have not been characterized quantitatively. Inhibition of
ANGPTL3 either by antisense oligonucleotides (8) or by
blocking antibodies (9) is an emerging pharmacological
approach to reduce the levels of all atherogenic lipoproteins,
with no apparent side effect in phase I trials (8, 9).
The low levels of TG and HDL-c in FHBL2 subjects
can be explained by the role of ANGPTL3 as an inhibitor
of both lipoprotein lipase (LPL) (10) and endothelial li-
pase (EL) (11). LPL plays a critical role in hydrolyzing TG
carried by very LDL (VLDL) and chylomicrons in the
circulation (10, 12). EL binds to heparin-sulfate pro-
teoglycans on the endothelial cell surface to increaseHDL
retention and delipidation via its phospholipase activity
(10–12). Thus, mutations in ANGPTL3 result in in-
creased activity of lipases, an effect that reduces plasma
TG and HDL-c levels (12, 13). However, LPL and EL do
not affect cholesterol homeostasis; thus, the increased
activity of these lipases cannot directly explain the reduced
LDL-c levels. Mice without ANGPTL3 demonstrate in-
creased remnant clearance via noncanonical pathways,
whichmight account for the reduction in LDL-c (14–16). It
was also shown that homozygous carriers of ANGPTL3
mutations have an increased fractional catabolic rate of
LDL, although the mechanism bywhich ANGPTL3 loss of
functionmutations promote increased LDL clearance is not
clear (2, 4). An increased LDL fractional catabolic rate was
also demonstrated in subjects with familial combined
hypobetalipoproteinemia type 1 (FHBL1) owing to dif-
ferent truncated apolipoprotein B (apoB) species (17); thus,
suggesting a possible common mechanism by which low
LDL-c levels, regardless of the primary genetic cause, un-
dergo accelerated LDL receptor clearance.
Proprotein convertase subtilisin kexin type 9 (PCSK9)
is a plasma protein that binds to the LDL receptor
(LDLR) and targets it for lysosomal degradation (18, 19),
leading to reduced cellular uptake of LDL (19–21).
Additionally, PCSK9 affect intestinal and hepatic pro-
duction of TG-rich lipoproteins (22–24). Plasma PCSK9
is in two main monomeric forms, a mature (intact) het-
erodimer (62+13 kDa) and a shorter heterodimer
(55+13 kDa), resulting from the proteolytic cleavage by
the enzyme furin (25, 26). Furin-cleaved PCSK9 loses the
N-terminal region of the catalytic domain (up to amino
acid 218) (26) and has reduced LDLR degradation activity
compared with the mature form (26–29). We, and others,
have shown that mature PCSK9 circulates predominantly
in association with LDL-size particles (24, 25). PCSK9
inhibition with monoclonal antibodies is an emerging
therapy to lower LDL-c in patients with atherosclerotic
cardiovascular disease or familial hypercholesterolemia
(FH) who require additional LDL-c lowering (30). The
effect of genetically low LDL levels on plasma PCSK9 and
its molecular forms and function has not been described.
We used different regressionmodels to study the effect of
ANGPTL3 levels on plasma lipids and lipoproteins in 19
families with ANGPTL3 mutations. We demonstrate that
ANGPTL3 levels correlate strongly with total choles-
terol, HDL-c, TG, HDL particle numbers (HDL-p), and
LDL particle numbers (LDL-p) when ANGPTL3 levels
are ,25% of normal and with VLDL particle numbers
(VLDL-p) when ANGPTL3 levels are ,58% of normal.
These regressionmodels likely represent a biologic threshold
for the effect of ANGPTL3 on lipoprotein metabolism. We
also show the existence of a reciprocal regulation mecha-
nism, by which low LDL levels result in reduced PCSK9
activity, which can lead to increased LDL particle clearance.
Methods
Subjects and samples
The study cohort was composed of 127 subjects, including 7
homozygous and 62 heterozygous carriers of the ANGPTL3
mutation p.S17* and 58 noncarrier relative controls from 19 dif-
ferent families. The family structure and relationships are shown in
Supplemental Fig. 1.All subjectswere identified in the populationof
Campodimele (Italy), as previously described (5), with institutional
review board approval from Sapienza University of Rome. For
studies of PCSK9 metabolism, we also used a cohort of FHBL1
subjects carrying different truncated apoB species with institutional
review board approval from the University of Palermo.
Plasma lipid and protein determinations
Plasma lipids were measured using standard techniques (5),
and LDL-c valueswere calculated using the Friedewald formula.
An enzyme-linked immunosorbent assay (ELISA) method using
an assay developed in-house assessed the ANGPTL3 plasma
concentration, as previously reported (31), or using a com-
mercially available ELISA kit (R&D Systems, Minneapolis,
MN). The lipoprotein particle concentration and size were
determined using nuclear magnetic resonance by LipoScience
(Raleigh, NC), as previously described (32). The PCSK9
levels were measured using commercially available ELISA
kits, according to the manufacturer’s instructions (MBL In-
ternational, Woburn, MA). LDL-bound PCSK9 levels were
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measured as recently described (33). In brief, rabbit polyclonal
antibodies binding to the C-terminal region of PCSK9 (Abgent,
San Diego, CA) were bound to microtiter well plates, and
EDTA plasma was added at a 1:50 dilution (40 mL/well) for
75 minutes. For LDL-bound PCSK9 detection, we used bio-
tinylated goat anti-human apoB-100 antibody (Academy Bio-
medical Co., Houston, TX). The results are reported as relative
light units in 100ms after subtraction of the background relative
light units. For size-exclusion chromatography (fast protein
liquid chromatography), we used a Superose 6, 10/300GL
column (GE Healthcare Life Sciences, Pittsburgh, PA), as pre-
viously described (34).
Western blotting
Plasma samples were run through amultiple affinity removal
column, Agilent Hu-14 column, to deplete the top 14 major
proteins (Hu-14; Agilent, Santa Clara, CA). The samples were
loaded onto 4% to 12% Tris-acetate sodium dodecyl sulfate
gels (Invitrogen, Carlsbad, CA) for electrophoretic separation.
Proteins were transferred onto a nitrocellulose membrane.
Rabbit a-PCSK9 primary antibody (MBL International) and
goat a-rabbit horseradish peroxidase–conjugated (Sigma-
Aldrich, St. Louis, MO) secondary antibodies were used to
detect target proteins. The signal was detected using an en-
hanced chemiluminescent solution made in-house using p-
coumaric acid, luminol, and hydrogen peroxide.
PCSK9 cleavage by furin
Recombinant PCSK9 was isolated as previously described
(35) and then incubated at 2mMtogether with furin (40 nM) for
6 hours at room temperature. Cleavage reaction was performed
in 50 mM Tris/150 mM NaCl with 4 mM CaCl2. Reaction
products were analyzed using 4% to 12% Tris-acetate sodium
dodecyl sulfate gels (Invitrogen) using rabbit a-PCSK9 primary
antibody, as described in the previous section.
PCSK9 binding to LDLR
Recombinant, histidine-tagged PCSK9 was competed
against increasing concentrations of purified plasma PCSK9
(LDL-bound or apoB-free) for binding to the epidermal growth
factor-like AB domain of the LDLR, using a commercially
available kit and following the manufacturer’s instructions
(MBL International).
Statistical analysis
Continuous variables are summarized as the mean 6 stan-
dard deviation for each ANGPTL3 mutation group. Multiple
regression models and generalized estimating equations (GEEs)
were used to estimate the association of plasma measurements
to ANGPTL3 levels and the mutation status and tested using
Wald statistics. Pearson’s correlation analysis was used for the
association of ANGPTL3 with the plasma measurements
(36–38). The association of ANGPTL3 and lipoproteins of
interest was modeled using the multivariate adaptive regression
splines (MARS) methods that assume the expected mean of the
lipoprotein is a piecewise linear function of ANGPTL3 and age
(39, 40). This model allows the strength of the correlation and
regression slope of ANGPLT3 for the lipoprotein to change
between different ranges of ANGPTL3 values. MARS performs
variable selection and will remove ANGPTL3 and/or age from
themodel if they are not predictive. Threemodelingmethods are
represented in the scatterplots to visually compareMARS to the
Table 1. Characteristics of ANGPTL3 Cohort (n = 127)
Characteristic Noncarriers (n = 58) Heterozygotes (n = 62) Homozygotes (n = 7)
Age, y 61 6 21 51 6 20 48 6 20
Female sex, % 39.7 40.3 42.8
ANGPTL3, ng/dL 259.4 6 134.9 123.9 6 100.1 0 6 0
Total cholesterol, mg/dL 187.5 6 25.5 167.2 6 31.6 82.4 6 12.1
HDL-c, mg/dL 69.6 6 15.1 55.4 6 13.7 27.8 6 8.1
TG, mg/dL 80.8 6 39.1 74.3 6 40.6 32.4 6 4.1
VLDL-p concentration, nmol/L 45.5 6 17.5 34.9 6 13.0 11.9 6 4.2)
HDL-p concentration, nmol/L 21.3 6 5.9 19.1 6 5.0 12.4 6 2.7)
LDL-p concentration, nmol/L 886 6 210 766 6 250 563 6 75)
LDL-c, mg/dL 102.2 6 24.7 97.3 6 28.1 48.3 6 15.3
Lipoprotein(a), mg/dL 21.3 6 30.7 23.0 6 28.4 20.7 6 25.1
VLDL size, nm 51.7 6 5.0 52.7 6 4.9 NA
LDL size, nm 20.4 6 0.7 20.5 6 0.6 19.8 6 0.2
HDL size, nm 9.2 6 0.5 8.9 6 0.5 9.4 6 0.2
Creatinine, U/L 1.10 6 0.19 1.12 6 0.18 1.03 6 0.13
Glucose, mg/dL 101.5 6 18.8 99.2 6 28.7 86.8 6 5.9
ALT, U/L 30.9 6 8.7 28.7 6 6.0 29.7 6 5.2
AST, U/L 29.1 6 11.9 29.0 6 11.9 36.5 6 4.9
ApoB, mg/dL 87.6 6 22.9 84.4 6 20.7 47.1 6 13.3
Apolipoprotein AI, mg/dL 179.9 6 23.9 163.7 6 27.8 77.2 6 18.9
Weight, kg 68.1 6 12.2 73.2 6 15.5 70.1 6 12.8
Height, m 1.57 6 0.1 1.62 6 0.09 1.58 6 0.08
BMI, kg/m2 27.6 6 4.9 27.9 6 5.0 28.1 6 7.3
PCSK9, ng/mL 207.1 6 59.1 173.1 6 63.3 144.3 6 30.9
LDL-bound PCSK9, RLU 12,608 6 5204 12,358 6 5168 6131 6 2008
Data presented as mean 6 standard deviation.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; NA, data not available; RLU, relative light units.
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GEE linear regression slopes and local polynomial regres-
sion loess curves. In most cases, MARS selected a model
representing a linear approximation to the loess smoothing
curve but provided more interpretability than the non-
parametric locally weighted scatterplot smoothing (loess)
method. The MARS analysis is based on the best linear
approximation of a curve nonparametric model; therefore,
the change point for the slopes is considered the best estimate.
Statistical analyses were performed using R, version 3.2.2 (R
Foundation, Vienna, Austria). Additional details regarding
the statistical methods are provided in the Supplemental
Data.
Results
Group comparison
The demographic data and clinical characteristics
of the carriers and noncarriers of ANGPTL3 mutations
are listed in Table 1. Plasma ANGPTL3 levels were
undetectable in the homozygotes and averaged 124 6
100 ng/dL among the heterozygotes and 2596 135 ng/dL
among the noncarriers. Homozygotes had lower levels of
all plasma lipid and lipoprotein parameters measured,
except for lipoprotein(a) level and HDL size, and het-
erozygotes had only a mild hypolipidemic phenotype
(Table 1; Supplemental Fig. 2). A summary of P values
fromWald test statistics for the group comparisons is given
in Supplemental Table 1.
Multiple GEE linear regression analyses
We used Pearson’s correlation coefficients and GEE
regression coefficients with plasma measurements as de-
pendent variables and ANGPTL3 as the independent
variable to study whether ANGPTL3 levels correlate with
the changes in plasma lipids levels and lipoprotein particle
concentration. Figure 1(a) and 1(b) demonstrates that the
total cholesterol and HDL-c levels correlate with the
ANGPTL3 levels (r = 0.37, P = 0.012, and r = 0.33, P =
0.005, respectively), but theTG levels do not correlatewith
the ANGPTL3 levels [Fig. 1(c)]. Figure 1(d–f) shows that
VLDL-p, HDL-p, and LDL-p also correlate with the
ANGPTL3 levels (r = 0.42, P , 0.001, r = 0.26, P =
, 0.001, and r = 0.3, P = 0.028, respectively). A summary
of Pearson’s correlation coefficients, regression coefficient,
and P values is presented in Supplemental Table 2. Similar
results were obtained when the homozygotes were ex-
cluded from the regression model (Supplemental Fig. 3).
MARS analyses
Despite the relevant correlations between ANGPTL3
levels and plasma lipid or lipoprotein concentrations
(Fig. 1), heterozygotes exhibit normal levels of many of
these measurements (Supplemental Fig. 2), representing a
lack of a clear gene–dosage effect of ANGPTL3, as
previously reported (5). A curve fit model (Fig. 2, green
lines) suggests that, at low levels, ANGPTL3 strongly
Figure 1. Scatterplot with univariate GEE linear regression slopes (blue) of ANGPTL3 levels against (a) total cholesterol, (b) HDL-c, (c) TG, (d)
VLDL-p, (e) HDL-p, and (f) LDL-p. P values from Wald test for the slope. b, univariate GEE regression coefficients; conc., concentration; r,
Pearson’s correlation coefficients.
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correlates with the plasma lipid levels and lipoprotein
concentrations but that at higher values, these correla-
tions are lost or become weaker. To approximate the
curve fit shown in green into linear slopes, we used a
model that allows for different correlation coefficients at
low and high ANGPTL3 levels, known as MARS. Thus,
instead of just one regression line with one slope, this
model allows for several regression lines at a range of
ANGPTL3 levels, as explained in the Supplemental Data.
MARS analysis (Fig. 2, red line) demonstrated that the
levels of plasma lipids and lipoprotein (total cholesterol,
HDL-c, TG, HDL-p, and LDL-p) correlate strongly with
the ANGPTL3 level when the latter is,60 ng/dL (~25%
of normal ANGPTL3 levels), and VLDL-p correlates
strongly with the ANGPTL3 level when the latter is
,138 ng/dL (~58% of normal ANGPTL3 levels). All
plasma measurements, aside from TG levels, showed a
threshold effect, even when the homozygotes were ex-
cluded from the regression model, with the main change
being a slightly higher threshold levels of ANGPTL3
(Supplemental Fig. 4). The MARS model fit R-squared
(r2) and equations of regression lines denoting the red
slopes are summarized in Supplemental Table 3.
Effect of low LDL on plasma PCSK9
Figure 3(a) shows a moderate reduction in plasma
PCSK9 levels, a knownmodulator of LDLmetabolism, in
heterozygotes compared with noncarriers (216.4%; P =
0.025), in homozygotes compared with noncarriers
(230.5%; P = 0.001), and in heterozygotes compared with
homozygotes (216.6%; P = 0.0069). The PCSK9 levels
correlatedwith both LDL-c (r=0.245,P=0.015) and apoB
(r = 0.41; P , 0.001) levels (Supplemental Fig. 5). Im-
munoblotting of the molecular forms of PCSK9 in plasma
[Fig. 3(b)] showed that homozygotes have reduced levels of
themature, intact form of PCSK9 and increased levels of its
furin-cleaved form. This finding was not explained by
alterations in plasma furin function, because no differences
were found in furin activity between the carriers and
noncarriers of the ANGPTL3 mutations (data not shown).
To study whether this phenomenon depends on low
ANGTPL3 levels or low LDL levels (regardless of its pri-
mary genetic cause), we analyzed the total PCSK9 levels
and its molecular forms in hypolipidemic subjects with
FHBL1 due to apoB truncations (range, 1% to 80% of
normal apoB), low LDL-c levels, and normal ANGPTL3
levels (the clinical characteristics of this cohort are listed in
Supplemental Table 4). Figure 3(c) shows a moderate re-
duction in plasma PCSK9 levels in subjects with truncated
apoB compared with controls (216.0%; P = 0.017).
Analysis of the molecular forms of PCSK9 in plasma
[Fig. 3(d)] demonstrated that subjects with truncated apoB
have reduced levels of the mature form of PCSK9 and
increased levels of the furin-cleaved form.
Figure 2. Scatterplot with nonparametric smoothed local polynomial regression fit (green) and MARS model fit (red) of ANGPTL3 levels against
(a) total cholesterol, (b) HDL-c, (c) TG, (d) VLDL-p, (e) HDL-p, and (f) LDL-p. b, univariate GEE regression coefficients; conc., concentration; r,
Pearson’s correlation coefficients.
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To further characterize the effect of LDL on PCSK9
function, we analyzed the distribution of PCSK9 mo-
lecular forms in plasma. Figure 4(a) shows the mature
form of PCSK9 is found predominantly in LDL frac-
tions, and the furin-cleaved PCSK9 is found mostly as
apoB-free. Our results further showed that LDL-bound
PCSK9 has a 70% stronger affinity toward the LDLR
than does apoB-free PCSK9 [Fig. 4(b)]. In addition,
subjects with either truncated apoB or homozygous
ANGPTL3 mutations showed lower levels of LDL-
bound PCSK9 compared with the heterozygotes and
noncarriers [Fig. 4(c)], and the levels of LDL-bound
PCSK9 correlated with the plasma apoB levels (Sup-
plemental Fig. 5). Finally, we tested the direct effect of
LDL on the ability of furin to cleave PCSK9 as a possible
explanation for why low LDL levels are coupled with
increased furin-cleaved PCSK9 in both ANGPTL3 and
apoB mutation carriers. Figure 4(d) demonstrates that
furin efficiently cleaves PCSK9 in vitro (control lane)
and that LDL (but not VLDL) inhibits this cleavage
reaction.
Discussion
We analyzed a unique cohort composed of individuals
carrying ANGPTL3 mutations and noncarrier relatives
as controls to gain insight into the effect of ANGPTL3
levels on the phenotypic expression of FHBL2. Our co-
hort showed a nonlinear pattern, as the homozygotes had
plasma lipid and lipoprotein particle concentrations 43%
to 70% lower than the concentrations in noncarriers, and
heterozygotes exhibited levels that were only 10% to
20% lower than those in noncarriers, as previously de-
scribed (5, 41). Our cohort also showed a weak corre-
lation between plasma ANGPTL3 levels and plasma
lipids and lipoprotein levels. We hypothesized that the
weak correlation between the ANGPTL3 levels and
plasma lipid/lipoprotein parameters is linked to a critical
concentration of plasma ANGPTL3 that triggers the
combined hypolipidemia trait. Our results have dem-
onstrated that ANGPTL3 levels correlate strongly and
linearly with plasma lipids, HDL-p, and LDL-p for
ANGPTL3 levels less than ;25% of normal and with
Figure 3. Effect of low LDL levels on plasma PCSK9: (a) group comparison for total PCSK9 levels in the ANGPTL3 cohort; (b) immunoblot (upper) and
quantification (lower) for plasma PCSK9 molecular forms in the ANGPTL3 cohort; (c) group comparison for total PCSK9 levels in the FHBL1 cohort; and
(d) Immunoblot (upper) and quantification (lower) for plasma PCSK9 molecular form in the FHBL1 cohort. *P , 0.05, **P , 0.01,***P , 0.001.
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VLDL-p at levels less than;58% of normal. The varying
ANGPTL3 concentrations associated with plasma lipid
and lipoprotein modulation can explain the lack of a
linear gene–dosage effect of ANGPTL3 mutations. The
FHBL2 phenotype seems to be dependent, not only on the
presence of mutations in ANGPTL3, but also, even more
to a critical reduction in plasma concentrations of
ANGPTL3. In support of a threshold effect of ANGPTL3
levels, it was recently shown that heterozygotes with
ANGPTL3 levels in the lowest tertile had reduced
myocardial infarction rates compared with subjects with
the highest tertile, who had similar event rates as non-
carriers (6).
In addition to the role of ANGPTL3 as an LPL and EL
inhibitor and its consequent effect on TGs and HDL-c
levels, animal and human studies have consistently re-
ported that ANGPTL3 deficiency and blockade are as-
sociated with lower LDL-c levels (4, 6–9, 42). Although
LDLR is not required for the ANGPTL3 effect on LDL-c
levels, the absence of LDLR in homozygous FH subjects
attenuates the LDL lowering effect of ANGPTL3 in-
hibition compared with the results in FH subjects with
residual LDLR function (43) or in normal volunteers (9).
Therefore, LDLR contributes to the plasma LDL low-
ering caused by reduced ANGPTL3 levels.
It was recently suggested that increased clearance of
remnants results in decreased production of LDL in
ANGPTL3-deficient animals, leading to a reduced LDL-c
level (14). If preferential clearance of large- and medium-
size LDL occurs, LDL-c, LDL-p, and LDL size should all
be reduced, a phenomenon that was recently described in
subjects treated with anti-PCSK9 antibodies (44) andwas
also seen in the homozygotes of our cohort (Table 1). Our
results have demonstrated mildly reduced plasma PCSK9
levels in ANGPTL3 mutation homozygotes and hetero-
zygotes compared with noncarriers. We further estab-
lished that LDL-bound PCSK9, which accounts for most
of the mature PCSK9 in plasma (25, 35), is dramatically
Figure 4. Effect of LDL binding on PCSK9: (a) size exclusion chromatography analysis of cholesterol (upper) and PCSK9 molecular forms
(immunoblot; lower) of a normolipidemic subject. (b) Competitive binding of PCSK9 to epidermal growth factor-like AB domain of the LDLR;
20 ng/mL recombinant histidine-tag PCSK9 (y-axis) was competed against increasing concentrations of LDL-bound or apoB-free PCSK9 (x-axis). (c)
Group comparison for LDL-bound PCSK9 levels. (d) In vitro reaction of PCSK9 cleavage by furin in the presence or absence of lipoproteins. *P ,
0.05, **P , 0.01, aP , 0.01 compared with noncarriers, bP , 0.01 compared with heterozygotes. EC50, half maximal effective concentration;
FPLC, fast protein liquid chromatography; RLU, relative light units.
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reduced in ANGPTL3mutation homozygotes and also in
FHBL1 subjects carrying truncated apoB. We have also
shown that LDL-bound PCSK9 has a stronger binding
affinity toward the LDLR compared with apoB-free
PCSK9. Kinetic studies in humans have shown that
both FHBL2 and FHBL1 subjects have increased LDL
clearance rates (2, 4, 17) and support the notion of a
common mechanism whereby low LDL levels, regardless
of their initial genetic cause, reduce PCSK9 activity to
further promote LDL clearance. Finally, we propose the
following mechanism to explain the link between LDL
levels and PCSK9 molecular forms and function. We
envision a scenario in which PCSK9 binding to LDL
protects it from cleavage by furin and preserve its LDLR-
binding capacity but that low LDL levels result in less
binding of PCSK9 to the particle, increased cleavage of
PCSK9 by furin, and reduced LDLR binding.
In conclusion, we have demonstrated that a critical
threshold of ANGPTL3 reduction is associated with
marked reductions in plasma lipid and lipoprotein con-
centration and that changes in compartmentalization of
plasma PCSK9 in plasma might contribute to the low LDL
phenotype by causing increasedLDL clearance.Our results
suggest that ongoing therapies (8, 9) directed at inhibiting
ANGPTL3 should target reductions of $75% in plasma
ANGPTL3 to replicate the full FHBL2-like phenotype.
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